Home > News > NanoSystems And B-M Squibb Agreement For NanoCrystal Technology
September 30th, 2003
NanoSystems And B-M Squibb Agreement For NanoCrystal Technology
Elan Corporation announced today that its drug delivery business unit, NanoSystems, and Bristol-Myers Squibb have signed a license agreement for NanoCrystal(TM) technology. This license will provide Bristol-Myers Squibb with access to NanoCrystal technology and the right to develop and commercialize products incorporating this technology.
Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells: NUS study shows that delivery of Epirubicin by nanodiamonds resulted in a normally lethal dosage of Epirubicin becoming a safe and effective dosage for treatment of liver cancer January 26th, 2015
Teijin to Participate in Nano Tech 2015 January 22nd, 2015
2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015
Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015